Identification of novel signal of clobazam‐associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis-Reference-Cited by-同舟云学术

Identification of novel signal of clobazam‐associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis

Published:2022-08-27 Issue:5 Volume:146 Page:623-627
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neuro Scandinavica

Author:

Sharma Akash¹,Kumar Anoop¹²^ORCID

Affiliation:

1. Department of Clinical Research Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India

2. Department of Pharmacology Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India

Publisher

Hindawi Limited

Subject

Neurology (clinical),Neurology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ane.13690

Reference21 articles.

1. Electronic Medicines Compendium.Summary of product characteristics for clobazam accord 10mg tablets. Accessed December 19 2021.https://www.medicines.org.uk/emc/product/5029/smpc#gref

2. Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice

3. Macroglossia Associated With Clobazam Administration: A Case Report and Literature Review

4. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System

5. Antiepileptic combination therapy with Stevens‐Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system;Frontiers in Pharmacology;2024-09-02

2. Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database;Frontiers in Pharmacology;2024-09-02

3. Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data;Frontiers in Pharmacology;2024-08-13

4. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database;Frontiers in Pharmacology;2024-07-01

5. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-06-07